2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 209

Joint Overuse in Patients with Rheumatoid Arthritis
Abstract Number: 210

Associations of Clinical Biomarkers with Radiographic Progression of Rheumatoid Arthritis (RA) in African Americans with Early Disease
Abstract Number: 211

Effects of Deep Haptic Massage in Fibromyalgia (pilot Study)
Abstract Number: 212

Utility of Mood Disorders Questionnaire in Fibromyalgia: Data from the Cleveland Clinic Fibromyalgia Registry
Abstract Number: 213

Relationship Between a History of Abuse and Fibromyalgia Symptoms and Severity: Data from the Cleveland Clinic Fibromyalgia Registry
Abstract Number: 214

How Well Do Visual Analogue Scales Used in the Fibromyalgia Impact Questionnaire (FIQ) Correlate with Other Measures of Pain, Fatigue, Sleep, Sleep Disturbance, Anxiety and Depression in Patients with Fibromyalgia
Abstract Number: 215

Opioid Treatment Pattern in a Community Based Rheumatology Clinic
Abstract Number: 216

Does Fibromyalgia Change the Evaluation of Spondyloarthritis Activity? A Meta-analysis of Observational Studies
Abstract Number: 217

Fibromyalgia and Multiple Switching of Biologics in Spondylarthritis
Abstract Number: 218

Effects of Tai Chi versus Aerobic Exercise on Mindfulness in Fibromyalgia
Abstract Number: 219

A Fibromyalgia Assessment Screening Tool on a Multidimensional Health Assessment Questionnaire (MDHAQ) Which Does Not Include a Self-Report RADAI Painful Joint Count (RADAI), FAST3nJC, Recognizes Fibromyalgia Similarly to Other FAST3 Indices Which Include a RADAI
Abstract Number: 220

A Positive Response to Nonpharmacological Therapies in Patients with Fibromyalgia
Abstract Number: 221

Emergency Department Utilization for Fibromyalgia Patients
Abstract Number: 222

Acupuncture for Chronic Musculoskeletal Pain: A Review of Randomized Controlled Trials
Abstract Number: 223

Correlation Between Heart Rate Variability Parameters and Circulating Neuropeptides in Fibromyalgia

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.